



# Supplementary Materials: Durvalumab after Sequential High-Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity


Romana Wass, Maximilian Hochmair, Bernhard Kaiser, Brane Grambozov, Petra Feuerstein, Gertraud Weiß, Raphaela Moosbrugger, Felix Sedlmayer, Bernd Lamprecht, Michael Studnicka and Franz Zehentmayr



**Figure S1.** Non-inferiority trials test, whether an experimental intervention is as efficacious as standard treatment. Therefore, it is necessary to define a cut-off below which the experimental arm is regarded as “non-inferior”. In the current study, this value was set at +20% meaning that if the high-dose group had 20% or less excess pulmonary toxicity compared to standard treatment, it could be accepted as non-inferior. Hence, the one-sided 95% confidence interval may not include the range of 20% or higher.



**Figure S2.** In the high-dose cohort, moderate changes in FEV1 could be observed at six months after RT compared to baseline (=before RT):  $n = 39$ , T-test for paired samples.



**Figure S3.** In the high-dose cohort, moderate changes in DLCO could be observed. The statistically significant decrease at the end of RT compared to baseline (=before RT) recovered six months later:  $n = 39$ , T-test for paired samples.

Table S1. Patient match.

Patient Match: High Dose Patients = Red, SoC Patients Green						
Patient No.	Salzburg = 1, Vienna = 0	Age	Sex: Male = 1, Female = 0	0 = ECOG 0 or 1, 1 = ECOG 2 or Higher	Smoking Status:	Histology: 1 = SCC, 2 = AC, 3 = NOS
					1 = ex- or Current Smoker, 0 = Never Smoker	
1	1	62.7	0	0	1	2
31	0	52.79	0	0	1	2
11	0	56.35	0	0	1	2
2	1	59.3	0	0	1	1
17	0	56.96	0	0	1	1
14	0	59.83	0	0	1	1
4	0	49.92	0	0	1	1
3	1	61.1	0	0	1	2
5	0	57.01	0	0	1	2
8	0	53.3	0	0	1	2
27	0	55.14	0	0	1	2
33	0	57.96	0	1	1	2
4	1	71.93	0	0	1	2
6	0	65.01	0	0	1	2
5	1	73.98	0	0	1	1
25	0	72.9	0	0	1	2
6	1	69.37	0	0	1	1
13	0	59.35	0	0	1	1
10	0	74.71	0	0	1	1
7	1	72.93	0	0	1	2
2	0	79.47	0	0	1	2
8	1	69.73	0	0	0	1
9	1	69.21	0	0	1	2
3	0	66.51	0	0	1	2
10	1	72.54	0	0	1	2
28	0	74.62	0	0	1	2
11	1	73.68	0	0	0	2
12	0	80.76	0	0	0	3
12	1	70.09	0	0	1	2
18	0	69.1	0	0	1	2
13	1	64.95	1	0	1	1
14	1	63.6	1	0	1	1
7	0	63.17	1	0	1	1
15	1	67.09	1	0	1	2
1	0	75.74	1	0	1	2
16	1	77.22	1	0	0	2
17	1	70.98	1	0	1	2
19	0	62.72	1	0	1	2
18	1	70.56	1	0	1	1
15	0	67.09	1	0	1	1
19	1	32.61	1	0	1	2
9	0	46.54	1	0	1	1
20	1	68.74	1	0	1	1
16	0	62.81	1	0	1	1

21	1	59.06	1	0	1	1
34	0	52.6	1	0	1	1
22	1	66.08	1	0	1	1
20	0	65.91	1	0	1	1
23	1	70.24	1	0	1	2
21	0	69.16	1	0	1	2
24	1	63.16	1	0	1	1
23	0	66.05	1	0	1	3
25	1	58.89	1	0	1	2
26	1	79.54	1	0	1	1
22	0	76.87	1	0	1	1
27	1	52.63	1	0	0	2
28	1	71.00	1	0	1	1
29	1	73.11	1	0	1	1
29	0	71.09	1	0	1	1
30	1	72.73	1	0	1	2
31	1	56.86	1	0	1	2
24	0	61.71	1	0	1	2
32	1	62.79	1	0	1	1
30	0	66.83	1	0	1	1
33	1	83.41	1	0	1	2
34	1	50.97	1	0	1	2
32	0	46.67	1	0	1	3
35	1	56.2	1	0	1	2
35	0	60.52	1	0	1	2
36	1	63.23	1	0	1	2
26	0	62.92	1	0	1	2
37	1	72.79	1	0	0	2
38	1	68.01	1	0	1	2
39	1	57.54	1	0	1	2
40	1	66.83	1	0	1	2
41	1	59.89	1	0	1	1
36	0	56.03	1	0	1	1
42	1	62.09	1	0	1	2